Breast Cancer (Female) - Diagnosis - NHS Choicesdoi:http://www.nhs.ukIf you notice a lump in your breast or any change in the appearance, feel or shape of your breasts, visit your GP.NHS ChoicesDepartment of Health
A case–control study to estimate the impact on breast cancer death of the breast screening programme in Wales OBJECTIVES: The aim of this study was to estimate the effect of service screening, as provided by the NHS breast screening programme, on breast cancer mort... HM Fielder,D Brook,J...
阅读量: 16 作者: U. Macleod,S. Ross,C. J. Twelves,C. Gillis,G. C. M. Watt 展开 摘要: Breast cancer care: Does the NHS discriminate against women living in deprived areas? - European Journal of Cancer 展开 DOI: 10.1016/S0959-8049(98)80306-7 被引量: 13 年份: 1998 收藏...
Cumulative risk for contralateral breast cancer was 26.5% in 20 years. Five and 10-year all-cause survival was 64.9% (95% confidence interval [CI] = 54.8–76.8) and 49.8% (95%CI = 39.3–63.0). Breast cancer–specific 10-year survival was 64.2% (95% CI = 53.5–77.0%)...
Genome-wide association studies have identified breast cancer risk variants in over 150 genomic regions, but the mechanisms underlying risk remain largely unknown. These regions were explored by combining association analysis with in silico genomic featu
Instead, distinct low- and high-grade multistep models of breast cancer progression have been hypothesized [21]. The “low-grade like” progression pathway is characterized by recurrent loss of 16q (> 75%), gains of 1q; expression of hormone receptors (ER+, PR+), lack of HER2 ...
NHS临床指南CanadianTaskForceonPreventiveHealthCare BreastCancerScreeningRecommendations2011 WhoistheCTFPHC?•TheCanadianTaskForceonPreventiveHealthCare(CTFPHC)–Comprisedof14primarycareexperts–Establishedtodevelopclinicalpracticeguidelinesthatsupport primarycareprovidersindeliveringpreventivehealthcare–Identifyevidencegaps...
Breast cancer remains a significant scientific, clinical and societal challenge. This gap analysis has reviewed and critically assessed enduring issues and new challenges emerging from recent research, and proposes strategies for translating solutions in
Black women across the African diaspora experience more aggressive breast cancer with higher mortality rates than white women of European ancestry. Although inter-ethnic germline variation is known, differential somatic evolution has not been investigate
Nice said it did not approve Enhertu for metastatic breast cancer with low levels of HER2, a protein that promotes growth of cancer cells, after chemotherapy. Nice provides guidance for the NHS on the value for money of treatments. The cost-effectiveness is “above the upper end of the ran...